<DOC>
	<DOCNO>NCT00848783</DOCNO>
	<brief_summary>This study determine whether intraperitoneal ( IP ) Floxuridine effective patient advance stomach gastro-esophageal junction cancer treatment consist pre- post-surgery chemotherapy .</brief_summary>
	<brief_title>Irinotecan/Cisplatin , Potentially Curative Surgery With Without Floxuridine , Followed Capecitabine Stomach Gastro-esophageal Junction ( GEJ ) Cancers</brief_title>
	<detailed_description>A previous Phase-II trial conduct principle investigator ( ) , utilize preoperative chemotherapy intraperitoneal consolidation , conduct patient locally advance , potentially resectable gastric cancer cancer gastro-esophageal junction ( GEJ ) , stag T3N0 , T4N0 , TN1 TN2 disease . The data suggest patient locally advance gastric GEJ cancer , systemic induction therapy , curative surgery high Ro resection rate , IP adjuvant therapy , acceptable toxicity encourage survival outcome . The Medical Research Council Adjuvant Gastric Infusional Chemotherapy ( MAGIC ) trial also show perioperative chemotherapy - chemotherapy give surgery - provide significant survival benefit . The investigator hypothesize adjuvant intraperitoneal salvage cancer micrometastatic residue surgery contribute disease-free survival . The goal trial determine whether IP Floxuridine , add adjuvant postoperative chemotherapy , prolong patient 's survival . This tested randomize open-label trial .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<criteria>Only untreated patient histologically document gastric/GEJ adenocarcinoma , clinical American Joint Committee Cancer ( AJCC ) stage grouping ( 11 ) IBIV ( Mo ) CT scan laparoscopy/endoscopic ultrasound , eligible . Excluded patient need urgent surgery gastrointestinal obstruction , perforation hemorrhage . Both men woman &gt; = 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 02 , member ethnic group minority . Patients without another invasive malignancy , adequately treat basal cell squamous cell skin cancer , free 5 year insitu cervix cancer insitu cancer . Since immune deficiency increase risk terminal infection aggravate bone marrow suppressive therapy , patient must without active uncontrolled infection include HIV . Patients without psychiatric disorder may interfere consent and/or protocol followup . An adequate bonemarrow reserve ( absolute neutrophil count &gt; = 1,500/ mmL , thrombocytes &gt; = 100,000 mmL , hemoglobin &gt; = 9 gm/dL ) . Preserved liver renal function ( total serum bilirubin &lt; 2 mg/dL , SGOT/SGPT = &lt; 3x upper limit normal , alkaline phosphatase = &lt; 3x upper limit normal , blood urea nitrogen ( BUN ) = &lt; 30 mg/dL , serum creatinine concentration &lt; 1.5 mg/dL creatinine clearance &gt; = 50 mL/min ) require . Creatinine clearance normalize 1.73 M^2 BSA . The prothrombin time , activate partial thromboplastin time , thrombin time within range normal value . Since chemotherapeutic agent use know suspected teratogenic adverse effect , woman must pregnant breastfeeding . All female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy . All patient reproductive age may participate unless agree use effective medically acceptable contraceptive method . Patients without diagnosed Gilbert 's disease bilirubin level &gt; = 2.0 mg/dL , patient may excessive CPT11 toxicity . No prior severe reaction fluoropyrimidine therapy know hypersensitivity 5fluorouracil . Capecitabine ( Xeloda ) contraindicate patient severe renal impairment , i.e. , creatinine clearance 30 mL/min , determine CockcroftGault equation show page 15 ( ) Renal impairment . In patient moderate renal impairment ( creatinine clearance 3050 mL/min ) , develop course adjuvant treatment Capecitabine , drug decrease 75 % start dose . Patients without severe concurrent disease , cardiac condition respond medication , myocardial infarction within last 12 month , active infection uncontrolled pulmonary disease , disease judgment investigator would make patient inappropriate entry study . Patients sign write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>gastroesophageal junction</keyword>
	<keyword>stomach cancer</keyword>
	<keyword>intraperitoneal infusion</keyword>
	<keyword>capecitabine</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cisplatin</keyword>
	<keyword>floxuridine</keyword>
</DOC>